Human IGFBP-1 Antibody Summary
Applications
Human IGFBP-1 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Recombinant Human and Mouse IGFBP‑1 by Western Blot. Western blot shows 25 ng of Recombinant Human IGFBP-1 (Catalog # 871-B1), Recombinant Mouse IGFBP-1 (Catalog # 1588-B1) and Recombinant Human IGFBP-5 (Catalog # 875-B5). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human IGFBP-1 Monoclonal Antibody (Catalog # MAB675) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for IGFBP-1 at approximately 26 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 3.
View Larger
IGFBP‑1 Inhibition of IGF‑I-dependent Cell Proliferation and Neutralization by Human IGFBP‑1 Antibody. Recombinant Human IGFBP-1 (Catalog # 871-B1) inhibits Recombinant Human IGF-I (Catalog # 291-G1) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-I (6 ng/mL) activity elicited by Recombinant Human IGFBP-1 (5 µg/mL) is neutralized (green line) by increasing concentrations of Human IGFBP-1 Monoclonal Antibody (Catalog # MAB675). The ND50 is typically 10-40 µg/mL.
View Larger
Detection of Human IGFBP-1 by Western Blot Differentiation-dependent protein expression of PRL and IGFBP1 in culture supernatants of HDSC and THESC. Cells were stimulated in the absence or presence of cAMP and/or E2P4 for 3, 6, 9 and 12 days. Supernatants were collected and PRL and IGFBP1 protein concentrations were measured by ELISA and Western blotting, respectively. Normalization of protein concentrations, ELISA, and immunodetection of IGFBP1 on membranes were performed as mentioned in Materials and Methods. A) ELISA of PRL in HDSC and THESC. Data represent mean values ± SEM of three experiments performed in duplicates. * indicates p < 0.05 compared to negative control (n.c.) of the same day; n.s., not significant; # indicates p < 0.05 between cAMP-treated and cAMP/E2P4-stimulated cultures. PRL expression in controls and E2P4-treated THESC were below the detection limit and therefore omitted from the graph. B) Western blot showing IGFBP1 (32 kD) expression in HDSC and THESC. Marker bands (kD) are depicted on the left side. Representative examples are shown. Image collected and cropped by CiteAb from the following publication (https://rbej.biomedcentral.com/articles/10.1186/1477-7827-9-155), licensed under a CC-BY license. Not internally tested by R&D Systems.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IGFBP-1
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.
Human IGFBP-1 cDNA encodes a 259 amino acid (aa) residue precursor protein with a putative 25 aa residue signal peptide that is processed to generate the 234 aa residue mature protein. IGFBP-1 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. IGFBP-1 is expressed in liver, decidua, kidneys and is the most abundant IGFBP in amniotic fluid. Serum levels of IGFBP-1 are lowest after meals. Hepatocyte production of IGFBP-1 is regulated at the transcriptional level due to the affects of insulin and corticosteriods. IGFBP-1 binds equally well to IGF-I and IGF-II, with phosphorylated forms of IGFBP-1 exhibiting higher binding affinities.
- Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
- Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
Product Datasheets
Citations for Human IGFBP-1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
6
Citations: Showing 1 - 6
Filter your results:
Filter by:
-
IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1, and IGFBP1
Authors: X Li, N Niu, J Sun, Y Mou, X He, L Mei
FEBS Open Bio, 2020-11-09;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis.
Authors: Nijaguna M, Patil V, Urbach S, Shwetha S, Sravani K, Hegde A, Chandramouli B, Arivazhagan A, Marin P, Santosh V, Somasundaram K
J Biol Chem, 2015-08-05;290(38):23401-15.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Evaluation of human first trimester decidual and telomerase-transformed endometrial stromal cells as model systems of in vitro decidualization.
Authors: Saleh L, Otti GR, Fiala C, Pollheimer J, Knofler M
Reprod. Biol. Endocrinol., 2011-12-07;9(0):155.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
Authors: Hu H, Kwun J, Aizenstein BD, Knechtle SJ
Transplantation, 2009-06-27;87(12):1814-20.
Species: Human
Sample Types: Urine
Applications: Antibody Array Development -
Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance.
Authors: Borai A, Livingstone C, Mehta S, Zarif H, Abdelaal F, Ferns G
Clin. Biochem., 2009-05-20;0(0):.
Species: Human
Sample Types: Serum
Applications: ELISA Development, Western Blot -
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
Biochem. Biophys. Res. Commun., 2005-08-05;333(3):1011-6.
Species: Human
Sample Types: Recombinant Protein
Applications: Western Blot
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IGFBP-1 Antibody
There are currently no reviews for this product. Be the first to review Human IGFBP-1 Antibody and earn rewards!
Have you used Human IGFBP-1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
